Table of Content
1. INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CLINICAL PHARMACY SERVICES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2. MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL CLINICAL PHARMACY SERVICES MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL CLINICAL PHARMACY SERVICES MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3. MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
5.1 PESTAL ANALYSIS
5.2 PORTER’S FIVE FORCES
6. INDUSTRY INSIGHTS
7. REGULATORY FRAMWORK
8. GLOBAL CLINICAL PHARMACY SERVICES MARKET, BY SERVICE TYPE
8.1 OVERVIEW
8.2 CONSULTING
8.2.1 CLINICAL PROGRAM DEVELOPMENT
8.2.1.1. MEDICATION THERAPY MANAGEMENT
8.2.1.2. HEPATITIS C THERAPEUTIC CLASS MANAGEMENT
8.2.1.3. OPIOID MANAGEMENT
8.2.1.4. PAIN MANAGEMENT
8.2.1.5. IMPROVING AND ENHANCING MEDICARE STAR RATINGS
8.2.1.6. ADDRESSING PEDIATRIC BEHAVIORAL HEALTH POLYPHARMACY
8.2.1.7. OTHERS
8.2.2 DATA ANALYTICS & DATA AGGREGATION
8.2.2.1. EXAMINATION OF DATA CLAIMS
8.2.2.2. ANALYSIS EVIDENCE-BASED MEDICINE DATA
8.2.2.3. TRANSLATION OF INFORMATION
8.2.2.4. REVIEW OF DATA
8.2.2.5. UTILIZATION TRENDS
8.2.2.6. DISCREPANCIES IN DATA
8.2.2.7. IDENTIFICATION OF OUTLIERS
8.2.2.8. PAYMENT METHOD MODELING
8.2.2.9. DATA WAREHOUSING AND CUSTOMIZED DATA MANAGEMENT SOLUTIONS
8.2.2.10. EVALUATION OF MEDICATION SPEND
8.2.2.11. IDENTIFICATION OF FRAUD, WASTE, AND ABUSE
8.2.2.12. DESIGNING AND ANALYSING MORTALITY REVIEW PROCESSES
8.2.3 PIPELINE & BUDGET IMPACT FORECASTING
8.2.3.1. PIPELINE MONITORING
8.2.3.2. EVIDENCE-BASED MEDICINE REVIEW
8.2.3.3. MARKET INTELLIGENCE
8.2.3.4. PHARMACY & MEDICAL CLAIMS ANALYSIS
8.2.4 VALUE-BASED ARRANGEMENTS
8.2.5 OTHERS
8.3 PHARMACY MANAGEMENT
8.3.1 FORMULARY AND PRIOR AUTHORIZATION MANAGEMENT
8.3.1.1. EVIDENCE-BASED MEDICINE LITERATURE REVIEW
8.3.1.2. CONSIDERATION OF ECONOMIC IMPLICATIONS
8.3.1.3. DRUG MONOGRAPH CREATION
8.3.2 DRUG UTILIZATION REVIEW
8.3.3 CLINICAL CALL CENTER
8.3.3.1. OUTREACH AND ENROLLMENT CAMPAIGNS
8.3.3.2. TARGETED ADHERENCE COUNSELING
8.3.3.3. PROVIDER OUTREACH
8.3.3.4. COORDINATION OF BENEFITS WITH INSURERS
8.3.3.5. PRIOR AUTHORIZATION AND DRUG UTILIZATION REVIEW
8.3.3.6. INBOUND CUSTOMER SUPPORT, ISSUE RESOLUTION, AND CALL TRIAGE
8.3.3.7. APPOINTMENT AND REFILL REMINDER CALLS
8.3.3.8. CUSTOMER SATISFACTION SURVEYS AND HEALTH ASSESSMENTS
8.3.4 PROVIDER AND MEMBER OUTREACH
8.3.4.1. PRESCRIBER OUTREACH AND EDUCATION
8.3.4.1.1. OUTCOMES ANALYSIS, MONITORING, AND SERVICE TRACKING
8.3.4.1.2. REFILL REMINDER CALLS TO PRESCRIBERS
8.3.4.1.3. TRAINING AND EDUCATIONAL MATERIALS RELATED TO MEDICATION INITIATIVES
8.3.4.1.4. OTHERS
8.3.4.2. MEMBER OUTREACH
8.3.4.2.1. HEALTH RISK ASSESSMENTS
8.3.4.2.2. MEDICATION ADHERENCE OUTREACH CALLS
8.3.4.2.3. TARGETED ADHERENCE COUNSELING
8.3.4.2.4. COMPREHENSIVE AND TARGETED MEDICATION REVIEWS
8.3.4.2.5. HIGH-RISK MEDICATION INTERVENTIONS
8.3.4.2.6. MEMBER SATISFACTION SURVEYS
8.3.4.2.7. APPOINTMENT SCHEDULING AND REMINDERS
8.3.4.2.8. REFERRAL FOLLOW-UPS
8.3.4.2.9. BENEFIT COORDINATION
8.3.4.2.10. OTHERS
8.4 INPATIENTS SERVICES
8.4.1 MANAGEMENT OF DRUG INTERACTIONS
8.4.1.1. DRUG-DRUG INTERACTIONS
8.4.1.2. DRUG-FOOD INTERACTIONS
8.4.1.3. DRUG AND POISON INFORMATION SERVICES
8.4.1.4. OTHERS
8.4.2 PROVISION OF DRUG INFORMATION
8.4.2.1. DOSAGE REGIMES
8.4.2.2. FORMUARY INTERPRETATIONS
8.4.2.3. ADR MONITORING
8.4.2.4. OTHERS
8.4.3 DRUG THERAPY MONITORING
8.4.4 SELECTION OF DRUG THERAPY
8.4.5 OTHERS
9. GLOBAL CLINICAL PHARMACY SERVICES MARKET, BY END USERS
9.1 OVERVIEW
9.2 HOSPITALS
9.3 CLINICS
9.4 COMMUNITY PHARMACY
9.5 OTHERS
10. GLOBAL CLINICAL PHARMACY SERVICES MARKET, BY COUNTRY
10.1 GLOBAL CLINICAL PHARMACY SERVICES MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
10.1.1 NORTH AMERICA
10.1.1.1. U.S.
10.1.1.1.1. U.S. CLINICAL PHARMACY SERVICES MARKET, BY SERVICE TYPE
10.1.1.1.2. U.S. CLINICAL PHARMACY SERVICES MARKET, BY END USERS
10.1.1.2. CANADA
10.1.1.3. MEXICO
10.1.2 EUROPE
10.1.2.1. GERMANY
10.1.2.2. FRANCE
10.1.2.3. U.K.
10.1.2.4. ITALY
10.1.2.5. SPAIN
10.1.2.6. RUSSIA
10.1.2.7. TURKEY
10.1.2.8. BELGIUM
10.1.2.9. NETHERLANDS
10.1.2.10. SWITZERLAND
10.1.2.11. REST OF EUROPE
10.1.3 ASIA-PACIFIC
10.1.3.1. JAPAN
10.1.3.2. CHINA
10.1.3.3. SOUTH KOREA
10.1.3.4. INDIA
10.1.3.5. AUSTRALIA
10.1.3.6. SINGAPORE
10.1.3.7. THAILAND
10.1.3.8. MALAYSIA
10.1.3.9. INDONESIA
10.1.3.10. PHILIPPINES
10.1.3.11. REST OF ASIA-PACIFIC
10.1.4 SOUTH AMERICA
10.1.4.1. BRAZIL
10.1.4.2. ARGENTINA
10.1.4.3. REST OF SOUTH AMERICA
10.1.5 MIDDLE EAST AND AFRICA
10.1.5.1. SOUTH AFRICA
10.1.5.2. SAUDI ARABIA
10.1.5.3. UAE
10.1.5.4. EGYPT
10.1.5.5. ISRAEL
10.1.5.6. REST OF MIDDLE EAST AND AFRICA
10.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
11. GLOBAL CLINICAL PHARMACY SERVICES MARKET, SWOT AND DBR ANALYSIS
12. GLOBAL CLINICAL PHARMACY SERVICES MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: GLOBAL
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
12.3 COMPANY SHARE ANALYSIS: EUROPE
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
12.5 MERGERS & ACQUISITIONS
12.6 NEW PRODUCT DEVELOPMENT & APPROVALS
12.7 EXPANSIONS
12.8 REGULATORY CHANGES
12.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
13. GLOBAL CLINICAL PHARMACY SERVICES MARKET, COMPANY PROFILE
13.1 CIGNA
13.1.1 COMPANY OVERVIEW
13.1.2 REVENUE ANALYSIS
13.1.3 GEOGRAPHIC PRESENCE
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 CVS HEALTH
13.2.1 COMPANY OVERVIEW
13.2.2 REVENUE ANALYSIS
13.2.3 GEOGRAPHIC PRESENCE
13.2.4 PRODUCT PORTFOLIO
13.2.5 RECENT DEVELOPMENTS
13.3 UNITEDHEALTH GROUP
13.3.1 COMPANY OVERVIEW
13.3.2 REVENUE ANALYSIS
13.3.3 GEOGRAPHIC PRESENCE
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENTS
13.4 ANTHEM, INC.
13.4.1 COMPANY OVERVIEW
13.4.2 REVENUE ANALYSIS
13.4.3 GEOGRAPHIC PRESENCE
13.4.4 PRODUCT PORTFOLIO
13.4.5 RECENT DEVELOPMENTS
13.5 CENTENE CORPORATION
13.5.1 COMPANY OVERVIEW
13.5.2 REVENUE ANALYSIS
13.5.3 GEOGRAPHIC PRESENCE
13.5.4 PRODUCT PORTFOLIO
13.5.5 RECENT DEVELOPMENTS
13.6 SS&C TECHNOLOGIES, INC.
13.6.1 COMPANY OVERVIEW
13.6.2 REVENUE ANALYSIS
13.6.3 GEOGRAPHIC PRESENCE
13.6.4 PRODUCT PORTFOLIO
13.6.5 RECENT DEVELOPMENTS
13.7 KAISER FOUNDATION HEALTH PLAN, INC.
13.7.1 COMPANY OVERVIEW
13.7.2 REVENUE ANALYSIS
13.7.3 GEOGRAPHIC PRESENCE
13.7.4 PRODUCT PORTFOLIO
13.7.5 RECENT DEVELOPMENTS
13.8 MCKESSON CORPORATION
13.8.1 COMPANY OVERVIEW
13.8.2 REVENUE ANALYSIS
13.8.3 GEOGRAPHIC PRESENCE
13.8.4 PRODUCT PORTFOLIO
13.8.5 RECENT DEVELOPMENTS
13.9 MEDIMPACT DIRECT, LLC.
13.9.1 COMPANY OVERVIEW
13.9.2 REVENUE ANALYSIS
13.9.3 GEOGRAPHIC PRESENCE
13.9.4 PRODUCT PORTFOLIO
13.9.5 RECENT DEVELOPMENTS
13.10 MICRO MERCHANT SYSTEMS, INC.
13.10.1 COMPANY OVERVIEW
13.10.2 REVENUE ANALYSIS
13.10.3 GEOGRAPHIC PRESENCE
13.10.4 PRODUCT PORTFOLIO
13.10.5 RECENT DEVELOPMENTS
13.11 RITE AID CORP.
13.11.1 COMPANY OVERVIEW
13.11.2 REVENUE ANALYSIS
13.11.3 GEOGRAPHIC PRESENCE
13.11.4 PRODUCT PORTFOLIO
13.11.5 RECENT DEVELOPMENTS
13.12 TRIALCARD INCORPORATED
13.12.1 COMPANY OVERVIEW
13.12.2 REVENUE ANALYSIS
13.12.3 GEOGRAPHIC PRESENCE
13.12.4 PRODUCT PORTFOLIO
13.12.5 RECENT DEVELOPMENTS
13.13 WALGREENS BOOTS ALLIANCE, INC.
13.13.1 COMPANY OVERVIEW
13.13.2 REVENUE ANALYSIS
13.13.3 GEOGRAPHIC PRESENCE
13.13.4 PRODUCT PORTFOLIO
13.13.5 RECENT DEVELOPMENTS
13.14 LIFE HEALTHCARE
13.14.1 COMPANY OVERVIEW
13.14.2 REVENUE ANALYSIS
13.14.3 GEOGRAPHIC PRESENCE
13.14.4 PRODUCT PORTFOLIO
13.14.5 RECENT DEVELOPMENTS
13.15 INTERFACE CS
13.15.1 COMPANY OVERVIEW
13.15.2 REVENUE ANALYSIS
13.15.3 GEOGRAPHIC PRESENCE
13.15.4 PRODUCT PORTFOLIO
13.15.5 RECENT DEVELOPMENTS
13.16 HEALTHDIRECT PHARMACY SERVICES
13.16.1 COMPANY OVERVIEW
13.16.2 REVENUE ANALYSIS
13.16.3 GEOGRAPHIC PRESENCE
13.16.4 PRODUCT PORTFOLIO
13.16.5 RECENT DEVELOPMENTS
13.17 PRS, INC.
13.17.1 COMPANY OVERVIEW
13.17.2 REVENUE ANALYSIS
13.17.3 GEOGRAPHIC PRESENCE
13.17.4 PRODUCT PORTFOLIO
13.17.5 RECENT DEVELOPMENTS
13.18 GUIDEHOUSE
13.18.1 COMPANY OVERVIEW
13.18.2 REVENUE ANALYSIS
13.18.3 GEOGRAPHIC PRESENCE
13.18.4 PRODUCT PORTFOLIO
13.18.5 RECENT DEVELOPMENTS
13.19 CAREPATHRX
13.19.1 COMPANY OVERVIEW
13.19.2 REVENUE ANALYSIS
13.19.3 GEOGRAPHIC PRESENCE
13.19.4 PRODUCT PORTFOLIO
13.19.5 RECENT DEVELOPMENTS
13.20 EVERSANA
13.20.1 COMPANY OVERVIEW
13.20.2 REVENUE ANALYSIS
13.20.3 GEOGRAPHIC PRESENCE
13.20.4 PRODUCT PORTFOLIO
13.20.5 RECENT DEVELOPMENTS
13.21 OMNICELL
13.21.1 COMPANY OVERVIEW
13.21.2 REVENUE ANALYSIS
13.21.3 GEOGRAPHIC PRESENCE
13.21.4 PRODUCT PORTFOLIO
13.21.5 RECENT DEVELOPMENTS
13.22 US BIOSERVICES
13.22.1 COMPANY OVERVIEW
13.22.2 REVENUE ANALYSIS
13.22.3 GEOGRAPHIC PRESENCE
13.22.4 PRODUCT PORTFOLIO
13.22.5 RECENT DEVELOPMENTS
13.23 OPTUM SPECIALTY PHARMACY
13.23.1 COMPANY OVERVIEW
13.23.2 REVENUE ANALYSIS
13.23.3 GEOGRAPHIC PRESENCE
13.23.4 PRODUCT PORTFOLIO
13.23.5 RECENT DEVELOPMENTS
13.24 ACARIA HEALTH
13.24.1 COMPANY OVERVIEW
13.24.2 REVENUE ANALYSIS
13.24.3 GEOGRAPHIC PRESENCE
13.24.4 PRODUCT PORTFOLIO
13.24.5 RECENT DEVELOPMENTS
13.25 SENDERRARX
13.25.1 COMPANY OVERVIEW
13.25.2 REVENUE ANALYSIS
13.25.3 GEOGRAPHIC PRESENCE
13.25.4 PRODUCT PORTFOLIO
13.25.5 RECENT DEVELOPMENTS
13.26 AHF PHARMACY
13.26.1 COMPANY OVERVIEW
13.26.2 REVENUE ANALYSIS
13.26.3 GEOGRAPHIC PRESENCE
13.26.4 PRODUCT PORTFOLIO
13.26.5 RECENT DEVELOPMENTS
13.27 ELIXIR SPECIALITY
13.27.1 COMPANY OVERVIEW
13.27.2 REVENUE ANALYSIS
13.27.3 GEOGRAPHIC PRESENCE
13.27.4 PRODUCT PORTFOLIO
13.27.5 RECENT DEVELOPMENTS
13.28 ARDON HEALTH, LLC.
13.28.1 COMPANY OVERVIEW
13.28.2 REVENUE ANALYSIS
13.28.3 GEOGRAPHIC PRESENCE
13.28.4 PRODUCT PORTFOLIO
13.28.5 RECENT DEVELOPMENTS
13.29 VALUE SPECIALTY PHARMACY
13.29.1 COMPANY OVERVIEW
13.29.2 REVENUE ANALYSIS
13.29.3 GEOGRAPHIC PRESENCE
13.29.4 PRODUCT PORTFOLIO
13.29.5 RECENT DEVELOPMENTS
13.30 PRIME THERAPEUTICS LLC
13.30.1 COMPANY OVERVIEW
13.30.2 REVENUE ANALYSIS
13.30.3 GEOGRAPHIC PRESENCE
13.30.4 PRODUCT PORTFOLIO
13.30.5 RECENT DEVELOPMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST RELATED REPORTS
14. CONCLUSION
15. QUESTIONNAIRE
16. ABOUT DATA BRIDGE MARKET RESEARCH
